Loading

Journal of Cardiology and Clinical Research

Impact of Chemotherapy in Cancer-Related Venous Thromboembolism. Looking for Prediction

Editorial | Open Access | Volume 1 | Issue 1

  • 1. Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy
  • 2. Department of Systems Medicine, Medical Oncology, Tor Vergata Clinical Center, University of Rome “Tor Vergata”, V.le Oxford 81, 00133, Rome, Italy
+ Show More - Show Less
Corresponding Authors
Patrizia Ferroni, M.D, Ph.D, Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Via della Pisana
Keywords

Cancer, Chemotherapy, Venous thromboembolism

Citation

Ferroni P, Roselli M, Guadagni F (2013) Impact of Chemotherapy in Cancer-Related Venous Thromboembolism. Looking for Prediction. J Cardiol Clin Res 1: 1002

INTRODUCTION

Cancer patients are characterized by an acquired thrombophilic condition predisposing to increased risk of venous thromboembolism (VTE) [1]. Former studies have probably underestimated VTE incidence, since most of them were retrospectively conducted on patients cohorts recruited before the advent of targeted therapies, or have been focusing only on objectively confirmed symptomatic VTE. Recent research, in fact, pointed out to a higher incidence of VTE in the “real-world setting” than previously reported [2]. This might be related on improvements in computed tomography scanner technology, which has increasingly led to the detection of incidental VTE on scans performed for (re)staging of disease [3] and may have been caused, as well, by the introduction of novel therapeutic approaches with detrimental effects on vascular functions [2].

In this respect, the role played by chemotherapy in cancerrelated VTE is unquestionable, and both indirect and direct evidences point out to a strong association between VTE onset and timing or type of anticancer drugs used [4,5]. Indeed, the time course of VTE incidence after an initial cancer diagnosis is highest in the first 3-6 months (i.e. during possible administration of adjuvant chemotherapy), declining during remission at rates similar to those observed in the general population and increasing again at time of relapse and related treatment [6]. However, while the use of thromboprophylaxis in hospitalized patients is currently acknowledged by all major societies’ guidelines [7,8], it is still not recommended for ambulatory cancer patients receiving chemotherapy with only few exceptions, mainly represented by patients with multiple myeloma receiving thalidomide- or lenalidomide-based regimens or very selected high-risk patients with solid tumors receiving chemotherapy, in whom, according to the latest guidelines issued by the America Society for Clinical Oncology, “clinicians may consider LMWH prophylaxis on a case-by-case basis …... Consideration of such therapy should be accompanied by a discussion with the patient about the uncertainty concerning benefits and harms as well as dose and duration of prophylaxis in this setting” [8].

This latter concept is of particular concern in those segments of the population defined as “fragile”, meaning especially the elderly in whom risk and benefit of thromboprophylaxis stands over a particularly uncertain threshold as a result of comorbidities and impaired cardiovascular function. Cancer, in fact, is becoming an increasingly common problem in elderly patients and the number of older adults seeking treatment for cancer is considerably increasing. The chemotherapyassociated prothrombotic risk associated could find a favourable ground in elderly, who due to the presence of incidental cardiovascular risk factors (hypertension, diabetes, etc..) are more likely to develop thrombotic events [9], which might ultimately impact on active treatment, quality of life and increased demand for health carerelated costs.

Hence, the need for stratification techniques to identify high-risk patients who might benefit from thromboprophylaxis. Accordingly, efforts have been devoted to identify candidate biomarkers that may be used in VTE risk assessment [5,10-16]. However, no specific biomarker has been recognized, so far, as a predictor for VTE in cancer out-patients [17]. Indeed, some of them are interesting, but poorly feasible in a general practice setting, as in the case of soluble P-selectin, thrombin generation assays, tissue factor and microparticle measurements, which can not be routinely evaluated, but require second-level test performing laboratories and/or skilled personnel [12-14,16]. Other tests might have a clinical application, such as D-dimer, which has been shown to have a predictive role in cancer-associated VTE [10,11,15], but whose value is still debated due to low accuracy and positive predictive value (PPV), which allow just a limited prediction for an individual patient [18-20]. In this respect, we must acknowledge that a large variety of D-dimer assays are commercially available and that their poor standardization makes impossible direct comparison of results obtained with different D-dimer methods [20]. Overall, the enzyme-linked immunofluorescent assays are considered the goldstandard of D-dimer testing having the highest diagnostic accuracy for VTE exclusion. Lately, high-sensitive latex quantitative D-dimer assays have become available in the laboratory routine. Using one of such assay, we recently demonstrated that D-dimer testing was capable of predicting a first VTE episode with a PPV twice that reported by other authors, without any substantial loss in negative predictive value or test accuracy [21].

If the type of assay used is crucial, on the other hand, the definition of appropriate cutoffs is not less important. Recent reports, in fact, pointed out to the need to establish different cutoffs for young-middle aged patients or elderly, given that the latter category is characterized by several comorbidities (mainly related to cardiovascular risk) which might interfere with the predictive value of a given biomarker. For that reason, the definition of an age-adjusted cut-off for D-dimer has been proposed to improve VTE diagnostic work-up of older patients with clinically suspected deep venous thrombosis [22].

A final issue that must be addressed is that cancer patients are in a thrombophilic, proinflammatory state, regardless of the presence or absence of VTE clinical evidence and only concurrent risk factors (i.e., antineoplastic treatment) might definitive influence VTE development [23]. Thus, in our opinion, monitoring coagulation changes during the first chemotherapy cycle, more than the determination of a single point measurement at baseline, could provide a valid estimate of the associated prothrombotic risk and might help to identify patients susceptible of developing VTE during treatment [5,14]. Beside the search for new biomarkers, other authors have addressed the problem of identifying high-risk patients through the development and validation of clinical risk models. In 2008, Khorana and colleagues developed and validated a formalised risk assessment models for chemotherapyassociated VTE using a scoring systems weighted on the bases of the regression coefficients obtained from a derivation model [24]. This predictive score, assigns 2 points to very high risk (pancreatic or gastric) or 1 point to high risk cancer sites (lung, ovarian or bladder). In addition, 1 point each is assigned for: platelet count >350x109/L, leukocyte count >11x109/L, hemoglobin 35 kg/m2. Simple enough to be used in clinical practice and externally validated by independent groups [11,14,25], the Khorana score correctly assigns patients to the high-risk category, but fails to classify approximately 40% to 60% of patients (intermediate risk), in whom clinical decision making remains challenging. Consistent with these observations, expanded risk scoring models, in which points were added based either on laboratory tests [11] or on platinum-based or gemcitabine chemotherapy [25] were recently proposed. Nonetheless, clinical decision making for thromboprophylaxis in ambulatory cancer patients undergoing chemotherapy remains challenging and might not be justified in particular clusters of patients, such as those identified as “intermediate risk class” using the Khorana’s model, some of which are likely to be in high-risk, and could benefit from prophylaxis.

As discussed above, the development of the Khorana model for cancer-associated thrombosis was based on a multivariate logistic regression model and was, thus, based on a rigorous statistical approach. However, given the wide variety of clinical and laboratory features known to confer an increased VTE risk to cancer patients, we are witnessing a database increase in the number of variables. Accordingly, multifactorial analysis by common biostatistic techniques can be biased by low statistical power due to inadequate sample size even in the presence of large numbers. A second challenge arises from the estimation of chemotherapy effects for an extended period, as these survival outcomes may be estimated with high variability and may be difficult to interpret. This results in an urgent need for new generation of computational theories and tools to assist researchers in extracting knowledge from the growing volumes of data. Open discussion and specifically designed studies are needed to improve risk assessment models which may help identify ambulatory cancer patients who may benefit from outpatient VTE prophylaxis.

 

REFERENCES

1. Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013; 49: 1404-13.

2. Khorana AA, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013; 119: 648-55.

3. Khorana AA, O’Connell C, Agnelli G, Liebman HA, Lee AY. Subcommittee on Hemostasis and Malignancy of the SSC of the ISTH. Incidental venous thromboembolism in oncology patients. J Thromb Haemost. 2012; 10: 2602-4.

4. Di Nisio M, Ferrante N, De Tursi M, Iacobelli S, Cuccurullo F, Büller HR, et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost. 2010; 104: 1049- 54.

5. Roselli M, Ferroni P, Riondino S, Mariotti S, Laudisi A, Vergati M, et al. Impact of chemotherapy on activated protein C-dependent thrombin generation-Association with VTE occurrence. Int J Cancer. 2013.

6. Streiff MB. Association between cancer types, cancer treatments, and venous thromboembolism in medical oncology patients. Hematol Oncol. 2013; 11: 349-57.

7. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ. American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141: 7S-47S.

8. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2189-204.

9. Vergati M, Della-Morte D, Ferroni P, Cereda V, Tosetto L, La Farina F, et al.. Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer. Rejuvenation Res. 2013; 16: 224-31.

10. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, et al.. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009; 27: 4124-9.

11. Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al.. Prediction of venous thromboembolism in cancer patients. Blood. 2010; 116: 5377-82.

12. Ay C, Dunkler D, Simanek R, Thaler J, Koder S, Marosi C, et al.. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2011; 29: 2099-103.

13. van Doormaal F, Kleinjan A, Berckmans RJ, Mackman N, Manly D, Kamphuisen PW, et al.. Coagulation activation and microparticleassociated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost. 2012; 108: 160-5.

14. Ferroni P, Martini F, Portarena I, Grenga I, Riondino S, La Farina F, et al. Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolism in cancer patients - a pilot study. Support Cancer Care. 2012; 20: 2713-20.

15. Roselli M, Ferroni P, Portarena I, Riondino S, La Farina F, Formica V, et al. Predictive value of high-sensitive D-dimer determination for chemotherapy-associated venous thromboembolism in gastrointestinal cancer patients. Thromb Haemost. 2012; 108: 1243- 5.

16. Roselli M, Ferroni P, Rolfo C, Peeters M, Palmirotta R, Formica V, et al. TNF-α gene promoter polymorphisms and risk of venous thromboembolism in gastrointestinal cancer patients undergoing chemotherapy. Ann Oncol. 2013.

17. Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol. 2009; 29: 316-20.

18. Douma RA, van Sluis GL, Kamphuisen PW, Söhne M, Leebeek FW, Bossuyt PM, et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost. 2010; 104: 831-6.

19. Righini M, Perrier A, De Moerloose P, Bounameaux H. D-Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost. 2008; 6: 1059-71.

20. Tripodi A. D-dimer testing in laboratory practice. Clin Chem. 2011; 57: 1256-62.

21. Ferroni P, Martini F, Portarena I, Massimiani G, Riondino S, La Farina F, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer. 2012; 13: 482-7.

22. Douma RA, Tan M, Schutgens RE, Bates SM, Perrier A, Legnani C, et al. Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica. 2012; 97: 1507-13.

23. Ferroni P, Riondino S, Portarena I, Formica V, La Farina F, Martini F, et al. Association between increased tumor necrosis factor alpha levels and acquired activated protein C resistance in patients with metastatic colorectal cancer. Int J Colorectal Dis. 2012; 27: 1561-7.

24. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood. 2008; 111: 4902-7.

25. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012; 7: 291-2

Ferroni P, Roselli M, Guadagni F (2013) Impact of Chemotherapy in Cancer-Related Venous Thromboembolism. Looking for Prediction. J Cardiol Clin Res 1: 1002.

Received : 28 Jun 2013
Accepted : 01 Jul 2013
Published : 03 Jul 2013
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X